Last update 05 Dec 2024

AVID-100

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
AVID 100
Target
EGFR x Tubulin
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Tubulin inhibitors
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal Diseases
Active Indication
Breast CancerSquamous Cell Carcinoma
Inactive Indication
EGFR positive Non-squamous non-small cell lung cancerSquamous Cell Carcinoma of Head and NeckSquamous non-small cell lung cancer+ [1]
Originator Organization
Bristol-Myers Squibb FCT bêta, Inc.
Active Organization
Bristol-Myers Squibb FCT bêta, Inc.
Inactive Organization
Formation Biologics Corp.Formation Biologics Corp.
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC35H48ClN3O10S
InChIKeyANZJBCHSOXCCRQ-FKUXLPTCSA-N
CAS Registry139504-50-0

Related

1
Clinical Trials associated with AVID-100
NCT03094169 / TerminatedPhase 1/2
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin
100 Clinical Results associated with AVID-100
Login to view more data
100 Translational Medicine associated with AVID-100
Login to view more data
100 Patents (Medical) associated with AVID-100
Login to view more data
100 Deals associated with AVID-100
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Squamous Cell CarcinomaPhase 2
US
-06 Sep 2019
Breast CancerPhase 2
US
-12 Apr 2019
EGFR positive Non-squamous non-small cell lung cancerPhase 2
US
Formation Biologics Corp.Formation Biologics Corp.
01 Feb 2017
Squamous Cell Carcinoma of Head and NeckPhase 2
US
Formation Biologics Corp.Formation Biologics Corp.
01 Feb 2017
Squamous non-small cell lung cancerPhase 2
US
Formation Biologics Corp.Formation Biologics Corp.
01 Feb 2017
Triple Negative Breast CancerPhase 2
US
Formation Biologics Corp.Formation Biologics Corp.
01 Feb 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03094169 (AACR2019)
ManualManual
Phase 1/2
Carcinoma
EGFR Overexpression | ER Negative | PR Negative ...
View more
-
dgnfazbayt(cpcqppvvoj) = G3 asymptomatic lipase elevation, G4 reversible thrombocytopenia vpbixcdafq (iesadutjco )
View more
Positive
01 Jul 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free